Spots Global Cancer Trial Database for INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Official Title: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Study ID: NCT02977780

Conditions

Glioblastoma

Interventions

Temozolomide

Neratinib

QBS10072S

Study Description

Brief Summary: This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib * Temozolomide (temodar) * Neratinib * CC115 * QBS10072S

Detailed Description: This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the study drug works in treating a specific disease. "Investigational" means that the drug is being studied. In this research study, the investigators are looking to compare the effects, good and bad, of the standard of care with the three investigational agent sub-studies Abemaciclib, Neratinib, CC115 to help people with Glioblastoma including the specific molecular changes in the genes and proteins. The FDA has approved Temozolomide (temodar) as a treatment for this disease, however the FDA has not approved Abemaciclib, CC115, Neratinib, QBS10072S for any diseases.